相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Blocking of the PD-1/PD-L1 Interaction by a D-Peptide Antagonist for Cancer Immunotherapy
Hao-Nan Chang et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2015)
Immunotherapeutic Impact of Toll-like Receptor Agonists in Breast Cancer
Christine Zhang et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2015)
Targeted Activation of Toll-Like Receptors: Conjugation of a Toll-Like Receptor 7 Agonist to a Monoclonal Antibody Maintains Antigen Binding and Specificity
Adam J. R. Gadd et al.
BIOCONJUGATE CHEMISTRY (2015)
Cytosolic sensing of aberrant DNA: arming STING on the endoplasmic reticulum
Qiang Wang et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2015)
Therapeutic targeting of Toll-like receptors in cutaneous disorders
Nassim Matin et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2015)
The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment
Johanna M. Gostner et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2015)
Research progress of indoleamine 2,3-dioxygenase inhibitors
Tianze Jiang et al.
FUTURE MEDICINAL CHEMISTRY (2015)
Identification of Substituted Naphthotriazolediones as Novel Tryptophan 2,3-Dioxygenase (TDO) Inhibitors through Structure-Based Virtual Screening
Jian-Sung Wu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
α,β-Methylene-ADP (AOPCP) Derivatives and Analogues: Development of Potent and Selective ecto-5′-Nucleotidase (CD73) Inhibitors
Sanjay Bhattarai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway
Amy B. Dounay et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Structure-Based Design of Human TLR8-Specific Agonists with Augmented Potency and Adjuvanticity
Mallesh Beesu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors
Ute F. Roehrig et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
IDO inhibitors move center stage in immuno-oncology
Cormac Sheridan
NATURE BIOTECHNOLOGY (2015)
Combination cancer immunotherapy and new immunomodulatory targets
Kathleen M. Mahoney et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Oncolytic viruses: a new class of immunotherapy drugs
Howard L. Kaufman et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Big opportunities for small molecules in immuno-oncology
Jerry L. Adams et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Targeting the TGFβ pathway for cancer therapy
Cindy Neuzillet et al.
PHARMACOLOGY & THERAPEUTICS (2015)
Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1
Krzysztof M. Zak et al.
STRUCTURE (2015)
New immunotherapies targeting the PD-1 pathway
Jordan M. Chinai et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2015)
Inhibitors of the PD-1/PD-L1 Pathway Can Mobilize the Immune System: An Innovative Potential Therapy for Cancer and Chronic Infections
Ahmed F. Abdel-Magid
ACS MEDICINAL CHEMISTRY LETTERS (2015)
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity
Leticia Corrales et al.
CELL REPORTS (2015)
Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses
Paul A. Beavis et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Targeting STING pathways for the treatment of cancer
Claudia Gravekamp et al.
ONCOIMMUNOLOGY (2015)
A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
Robert D. Leone et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2015)
First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma
Jordi Rodon et al.
CLINICAL CANCER RESEARCH (2015)
Translating nucleic acid-sensing pathways into therapies
Tobias Junt et al.
NATURE REVIEWS IMMUNOLOGY (2015)
New Horizons in Therapeutic Antibody Discovery: Opportunities and Challenges versus Small-Molecule Therapeutics
Alison J. Smith
JOURNAL OF BIOMOLECULAR SCREENING (2015)
Directing the Immune System with Chemical Compounds
Rock J. Mancini et al.
ACS CHEMICAL BIOLOGY (2014)
Programmed Death-1: Therapeutic Success after More than 100 Years of Cancer Immunotherapy
Alexander Doemling et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2014)
Immune Modulation in Cancer with Antibodies
David B. Page et al.
ANNUAL REVIEW OF MEDICINE, VOL 65 (2014)
A Phase I Dose-Finding Study of the Novel Toll-like Receptor 8 Agonist VTX-2337 in Adult Subjects with Advanced Solid Tumors or Lymphoma
Donald W. Northfelt et al.
CLINICAL CANCER RESEARCH (2014)
Towards Next Generation Adenosine A2A Receptor Antagonists
G. Yuan et al.
CURRENT MEDICINAL CHEMISTRY (2014)
TGF-beta Signaling in Cancer Treatment
Isabel Fabregat et al.
CURRENT PHARMACEUTICAL DESIGN (2014)
Toll-like receptors as therapeutic targets for cancer
Johanna Holldack
DRUG DISCOVERY TODAY (2014)
Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors
Ute F. Roehrig et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
Adenosine pathway and cancer: where do we go from here?
Luca Antonioli et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2014)
Immunoregulatory activity of adenosine and its role in human cancer progression
Sylvia Muller-Haegele et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2014)
Discovery of N-((4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): A Highly Potent, Selective, and Orally Bioavailable Inhibitor of TGF-β Type I Receptor Kinase as Cancer Immunotherapeutic/Antifibrotic Agent
Cheng Hua Jin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Chemically Synthesized Molecules with the Targeting and Effector Functions of Antibodies
Patrick J. McEnaney et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2014)
Adenosine A2B receptor antagonist PSB603 suppresses tumor growth and metastasis by inhibiting induction of regulatory T cells
Wakako Kaji et al.
JOURNAL OF TOXICOLOGICAL SCIENCES (2014)
Genentech dives deeper into the next wave of cancer immunotherapies
Sarah Crunkhorn
NATURE REVIEWS DRUG DISCOVERY (2014)
The Yin and Yang of Toll-like receptors in cancer
J-P Pradere et al.
ONCOGENE (2014)
Crystal Structures and Structure Activity Relationships of Imidazothiazole Derivatives as IDO1 Inhibitors
Shingo Tojo et al.
ACS MEDICINAL CHEMISTRY LETTERS (2014)
Targeting Cancer-Derived Adenosine: New Therapeutic Approaches
Arabella Young et al.
CANCER DISCOVERY (2014)
Hostile, Hypoxia-A2-Adenosinergic Tumor Biology as the Next Barrier to Overcome for Tumor Immunologists
Michail V. Sitkovsky et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Co-blockade of immune checkpoints and adenosine A2A receptor suppresses metastasis
Arabella Young et al.
ONCOIMMUNOLOGY (2014)
A Phase I study of NLG919 for adult patients with recurrent advanced solid tumors
Asha Nayak et al.
Journal for ImmunoTherapy of Cancer (2014)
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment
Stefani Spranger et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Clinical application of genetically modified T cells in cancer therapy
Michael H. Kershaw et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2014)
Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma
Simon J. Dovedi et al.
BLOOD (2013)
Using macrophage activation to augment immunotherapy of established tumours
Z. G. Fridlender et al.
BRITISH JOURNAL OF CANCER (2013)
Necrostatin-1 blocks both RIPK1 and IDO: consequences for the study of cell death in experimental disease models
P. Vandenabeele et al.
CELL DEATH AND DIFFERENTIATION (2013)
Activin receptor-like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes
Jeong-Hwan Yoon et al.
EMBO MOLECULAR MEDICINE (2013)
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
Rikke B. Holmgaard et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies
Li Shi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Kynurenines in the CNS: recent advances and new questions
Laszlo Vecsei et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
ENTPD1/CD39 is a promising therapeutic target in oncology
J. Bastid et al.
ONCOGENE (2013)
Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors
Paul A. Beavis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Molecular signatures of T-cell inhibition in HIV-1 infection
Marie Larsson et al.
RETROVIROLOGY (2013)
Targeting Toll-like receptors: promising therapeutic strategies for the management of sepsis-associated pathology and infectious diseases
Athina Savva et al.
FRONTIERS IN IMMUNOLOGY (2013)
A novel peptide therapeutic targeting PD1 immune checkpoint with equipotent antagonism of both ligands and a potential for better management of immune-related adverse events
Pottayil Sasikumar et al.
Journal for ImmunoTherapy of Cancer (2013)
The roles of TGFβ in the tumour microenvironment
Michael Pickup et al.
NATURE REVIEWS CANCER (2013)
Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2
Supun M. Bakmiwewa et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
Demonstration of anti-tumor efficacy in multiple preclinical cancer models using a novel peptide inhibitor (Aurigene-012) of the PD1 signaling pathway
Pottayil G. Sasikumar et al.
CANCER RESEARCH (2012)
Molecular Pathways: Next-Generation Immunotherapy-Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
Daniel S. Chen et al.
CLINICAL CANCER RESEARCH (2012)
New developments in Toll-like receptor targeted therapeutics
Dympna J. Connolly et al.
CURRENT OPINION IN PHARMACOLOGY (2012)
Rational Design of 4-Aryl-1,2,3-Triazoles for Indoleamine 2,3-Dioxygenase 1 Inhibition
Ute F. Roehrig et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
The kynurenine system and immunoregulation
Yvette Mandi et al.
JOURNAL OF NEURAL TRANSMISSION (2012)
Crystal structures of STING protein reveal basis for recognition of cyclic di-GMP
Guijun Shang et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2012)
Influence of Tryptophan Contained in 1-Methyl-Tryptophan on Antimicrobial and Immunoregulatory Functions of Indoleamine 2,3-Dioxygenase
Silvia K. Schmidt et al.
PLOS ONE (2012)
Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase
Luc Pilotte et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Raising the Bar: The Curative Potential of Human Cancer Immunotherapy
Steven A. Rosenberg
SCIENCE TRANSLATIONAL MEDICINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors
David Meininger et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2011)
Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non-Small-Cell Lung Cancer
Primo N. Lara et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Tryptophan 2,3-Dioxygenase (TDO) Inhibitors. 3-(2-(Pyridyl)ethenyl)indoles as Potential Anticancer Immunomodulators
Eduard Dolusic et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Christiane A. Opitz et al.
NATURE (2011)
The Indoleamine-2,3-Dioxygenase (IDO) Inhibitor 1-Methyl-D-tryptophan Upregulates IDO1 in Human Cancer Cells
Christiane A. Opitz et al.
PLOS ONE (2011)
Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors
Mark J. Anderton et al.
TOXICOLOGIC PATHOLOGY (2011)
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
Xiangdong Liu et al.
BLOOD (2010)
Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists
Svetlana Hamm et al.
JOURNAL OF IMMUNOTOXICOLOGY (2009)
1-Alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: Development and Characterization of Adenosine A2B Receptor Antagonists and a New Radioligand with Subnanomolar Affinity and Subtype Specificity
Thomas Borrmann et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Discovery of Potent Competitive Inhibitors of Indoleamine 2,3-Dioxygenase with in Vivo Pharmacodynamic Activity and Efficacy in a Mouse Melanoma Model
Eddy W. Yue et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Therapeutic Targeting of Toll-Like Receptors for Infectious and Inflammatory Diseases and Cancer
Luke A. J. O'Neill et al.
PHARMACOLOGICAL REVIEWS (2009)
Synthesis and immunostimulatory properties of the phosphorothioate analogues of cdiGMP
Hongbin Yan et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Twelve immunotherapy drugs that could cure cancers
Martin A. ‘Mac’ Cheever
IMMUNOLOGICAL REVIEWS (2008)
Identification of RIP1 kinase as a specific cellular target of necrostatins
Alexei Degterev et al.
NATURE CHEMICAL BIOLOGY (2008)
Structures of PD-1 with its ligands: Sideways and dancing cheek to cheek
Gordon J. Freeman
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2
Eszter Lazar-Molnar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
Michal Marzec et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agionist, to activate innate immune responses in patients with advanced cancer
Arkadiusz Z. Dudek et al.
CLINICAL CANCER RESEARCH (2007)
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Andrew T. Parsa et al.
NATURE MEDICINE (2007)
Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors
Alexander J. Muller et al.
NATURE REVIEWS CANCER (2006)
Rapamycin analogs with differential binding specificity permit orthogonal control of protein activity
JH Bayle et al.
CHEMISTRY & BIOLOGY (2006)
Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy
AJ Muller et al.
NATURE MEDICINE (2005)
Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: Results from two phase III, randomized, vehicle-controlled studies
J Geisse et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2004)
Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity
LP Chen
NATURE REVIEWS IMMUNOLOGY (2004)
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
C Uyttenhove et al.
NATURE MEDICINE (2003)
分享论文
